Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.ppat.1008969 http://scihub22266oqcxt.onion/10.1371/journal.ppat.1008969 33119725!7595322!33119725     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33119725&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       PLoS+Pathog 2020 ; 16 (10): e1008969 Nephropedia Template TP {{tp|p=33119725|t=2020. "Trained immunity" from Mycobacterium spp exposure or BCG vaccination and COVID-19 outcomes |pdf=|usr=}}{{33119725}} gab.com Text "Trained immunity" from Mycobacterium spp exposure or BCG vaccination and COVID-19 outcomes JO: PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33119725 #FOAvip Protective variables for Coronavirus Disease 2019 (COVID-19) are unknown. "Trained immunity" of the populace as a result of Bacille Calmette-Guerin (BCG) vaccination policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning the measures of "trained immunity" or the heterologous cell-mediated immunity conferred by BCG vaccination has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any protective correlation with regard to BCG vaccination. Whereas, when we analyze the COVID-19 epidemiological data of European countries without any regard for BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of tuberculin immunoreactivity-a measure of cell-mediated immunity persistence as a result of Mycobacterium spp. (including BCG vaccine) exposure of the populations-is found consistently negatively correlated with COVID-19 infections and mortality. We seek to draw attention toward the inclusion of controls for underlying "trained immunity" and heterologous cell-mediated immunity prevalence that may be preexisting or resulting from the intervention (e.g., BCG vaccine) in such trials to arrive at more dependable conclusions concerning potential benefit from them. Twit Text FOAVip "Trained immunity" from Mycobacterium spp exposure or BCG vaccination and COVID-19 outcomes ????PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33119725 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33119725 #FOAvip English Wikipedia <ref>{{Cite pmid|33119725}}</ref> "Trained immunity" from Mycobacterium spp exposure or BCG vaccination and COVID-19 outcomes #MMPMID33119725 Singh S; Maurya RP; Singh RK PLoS Pathog 2020[Oct]; 16 (10): e1008969 PMID33119725show ga Protective variables for Coronavirus Disease 2019 (COVID-19) are unknown. "Trained immunity" of the populace as a result of Bacille Calmette-Guerin (BCG) vaccination policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning the measures of "trained immunity" or the heterologous cell-mediated immunity conferred by BCG vaccination has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any protective correlation with regard to BCG vaccination. Whereas, when we analyze the COVID-19 epidemiological data of European countries without any regard for BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of tuberculin immunoreactivity-a measure of cell-mediated immunity persistence as a result of Mycobacterium spp. (including BCG vaccine) exposure of the populations-is found consistently negatively correlated with COVID-19 infections and mortality. We seek to draw attention toward the inclusion of controls for underlying "trained immunity" and heterologous cell-mediated immunity prevalence that may be preexisting or resulting from the intervention (e.g., BCG vaccine) in such trials to arrive at more dependable conclusions concerning potential benefit from them. |*Immunity, Cellular[MESH] |*Vaccination[MESH] |BCG Vaccine/*immunology[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*immunology[MESH] |Humans[MESH] |Mycobacterium/*immunology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology[MESH]"Trained immunity" from Mycobacterium spp exposure or BCG vaccination(epmc).pdf DeepDyve Pubget Overpricing